Sydney, Australia – 8 August 2024 | LTR Pharma Limited (ASX: LTP) (“LTR Pharma” or “the Company”) is pleased to announce that SPONTAN®, its innovative nasal spray treatment for Erectile Dysfunction (ED), has been prescribed by a second men’s health expert in Australia under the Therapeutic Goods Administration’s (TGA) Special Access Scheme (SAS). This milestone is part of LTR Pharma’s strategic efforts to expand the reach of SPONTAN® and provide access to new ED treatments in the area of men’s health.
Key Highlights:
Approval of a Second Prescriber: Dr Tom Silva, a leading expert in men’s health, Senior Lecturer in General Practice at the University of Queensland, and Director of Kangaroo Point Medical Centre in Brisbane, is now authorised to prescribe SPONTAN® to select patients under the TGA’s SAS.
Strategic Engagement: LTR Pharma is actively engaging with a network of healthcare professionals to familiarise them with SPONTAN® and its clinical benefits over traditional orally-administered ED treatments.
Special Access Scheme: The TGA’s SAS provides a pathway for early access to innovative treatments like SPONTAN®, but it also will help as part of this strategic engagement to gather real-world data and increase awareness within the medical community.
Innovation for Unmet Needs in ED: SPONTAN® offers a new method for administering existing drugs, along with a faster onset of the effects and a reduced side effect profile compared to traditional oral PDE5 inhibitors. This makes it a valuable addition to the treatment options available for ED in men’s health.
Dr Tom Silva, Director of Kangaroo Point Medical Centre, stated: “SPONTAN meets the needs of my patients where regular PDE5 inhibitor tablets do not. Its fast onset of action, ease of use and improved side effect profile make it a valuable addition to our treatment options for erectile dysfunction.”
The adoption of SPONTAN® by healthcare professionals like Dr Silva underscores its potential as a game-changer in the treatment of ED. SPONTAN®’s nasal spray delivery allows for a lower dose of the PDE5 inhibitor than oral tablets, which may reduce the risk and duration of side effects while maintaining efficacy.
Lee Rodne, Chairman of LTR Pharma, commented: “We are thrilled to see SPONTAN being utilised by medical experts like Dr Silva. This represents another significant step in our strategy to introduce SPONTAN to the market through a carefully managed approach working with knowledgeable medical practitioners.”
This introduction of SPONTAN® aims to provide healthcare professionals with an effective new option for treating ED, while simultaneously expanding the product’s presence in the market.
About us:
About LTR Pharma:
LTR Pharma is focused on improving men’s health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma’s lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.
